Dyslipidemia

A study from investigators in Europe found the CCS, ACC/AHA, and NICE guidelines for statin use may be more effective at preventing ASCVD events than ESC/EAS or USPSTF guidelines.

A recent study found the lifetime risk of peripheral artery disease in black patients was around 30% while Hispanic and white patients had prevalence rates around 20%.

Initial PCSK9 inhibitor plus statin therapy helped hospitalized patients achieve LDL-C

A recent study found that county-level poverty prevalence correlated with both heart failure and coronary heart disease mortality rates.

Naeem Khan, MD, and Kiersten Combs, both of Astrazeneca, discuss how recent news from FDA and ESC Congress 2019 could impact dapagliflozin moving forward.

A recent study presented at ESC Congress 2019 found that a 1 unit increase in BMI at 18 years old translated to a hazard ratio of 1.10.

A recent study examining how genetic risk factors and lifestyle choices impact premature coronary artery disease found evidence that various factors play a greater role than genetics for younger patients.

A study presented at ESC Congress 2019 revealed childhood BMI, systolic blood pressure, and serum total cholesterol and triglycerides are positively associated with adult CVD.

A recent study found that expanding statin treatment to those with borderline risk of atherosclerotic cardiovascular disease and high LDL-C levels could prevent ASCVD events and be cost-effective on a population level.

A primary investigator-led discussion will tap into how invasive procedures have become more embraced in US cardiology.

Results of the phase 3 trial show that inclisiran reduced LDL cholesterol in patients with atherosclerotic cardiovascular disease.

Severe vitamin D deficiency in people with diabetes treated with dual antiplatelet therapy (DAPT) after an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) is associated with high residual platelet reactivity in patients taking the adenosine-diphosphate (ADP) antagonists ticagrelor or prasugrel, according to an exploratory study epublished on June 7 by Vascular Pharmacology.

The advent of newer antiplatelet agents and oral anticoagulants has allowed new regimens for secondary prevention of coronary artery disease. When combination therapy is needed, the bleeding risk is particularly pronounced, and the benefits and risks must be balanced for individual patients.

While results of COMPASS proved the efficacy of combination rivaroxban-plus-aspirin, it may not be the best treatment for every patient suffering from coronary or peripheral artery disease.

A team of investigators review global HCV infection rates in an attempt to quantify HCV-associated cardiovascular disease.

After showing a significant impact on reduction of cardiovascular events, a slew of subgroup analyses were performed examining use of icosapent ethyl using data derived from REDUCE-IT.

The investigative monoclonal antibody from Regeneron shows significant benefit for patients with the rare, severe homozygous familial hypercholesterolemia.

Trial investigator Deepak Bhatt, MD, MPH, discusses how use of rivaroxaban in a clinical setting has changed as a result of the COMPASS trial.

Lead investigator of REDUCE-IT trials discusses the impact of trial results and what that means for EPA-based treatments going forward.

Use of rivaroxaban (Xarelto) plus aspirin was found to reduce cardiovascular and major limb events in a secondary analysis of the COMPASS trial.

In a recent study, investigators from Johns Hopkins found that risks of peripheral artery disease remains elevated for 30 years after smoking cessation.